Jianming Zhang

发表

Fluorescent Visualization of Src by Using Dasatinib‐BODIPY

Shuai Liu, Zijuan Zhang, N. Gray, 2014, Chembiochem : a European journal of chemical biology.

Targeting cancer with small molecule kinase inhibitors

N. Gray, Jianming Zhang, Priscilla L. Yang, 2009, Nature Reviews Cancer.

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

John T. Powers, G. Daley, W. Jahnke, 2010, Nature.

Uveal melanoma: progress in molecular biology and therapeutics

Xianqun Fan, Jianming Zhang, S. Ge, 2020, Therapeutic advances in medical oncology.

Direct Targeting of β-Catenin by a Small Molecule Stimulates Proteasomal Degradation and Suppresses Oncogenic Wnt/β-Catenin Signaling.

Sam W. Lee, K. Westover, Xianming Deng, 2016, Cell reports.

Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer.

D. Sabatini, N. Gray, Qingsong Liu, 2010, Journal of medicinal chemistry.

Discovery of 1-( 4-( 4-Propionylpiperazin-1-yl )-3-( trifluoromethyl ) phenyl )-9-( quinolin-3-yl ) benzo [ h ] [ 1 , 6 ] naphthyridin-2 ( 1 H )-one as a Highly Potent

N. Gray, Qingsong Liu, W. Hur, 2014 .

Development of ATP-competitive mTOR inhibitors.

D. Sabatini, N. Gray, Qingsong Liu, 2012, Methods in molecular biology.

Discovery and Identification of Small Molecules as Methuosis Inducers with in Vivo Antitumor Activities.

Xianming Deng, Ting Zhang, Z. Wang, 2018, Journal of medicinal chemistry.

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1*

D. Sabatini, N. Gray, Qingsong Liu, 2009, Journal of Biological Chemistry.

Systematic Identification of Culture Conditions for Induction and Maintenance of Naive Human Pluripotency

R. Young, R. Jaenisch, N. Gray, 2014, Cell stem cell.

A structure-guided approach to creating covalent FGFR inhibitors.

Scott B Ficarro, Nathanael S Gray, Matthew Meyerson, 2010, Chemistry & biology.

Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase.

L. Flatauer, Sungjoon Kim, M. Warmuth, 2008, Bioorganic & medicinal chemistry letters.

An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRα and kit.

P. Jänne, N. Gray, Wenjun Zhou, 2012, Bioorganic & medicinal chemistry letters.

Activating mutations in ALK provide a therapeutic target in neuroblastoma

D. Gary Gilliland, Stefan Fröhling, Wendy B. London, 2008, Nature.

Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer

D. Kwiatkowski, Jianming Zhang, I. Malinowska, 2021, PloS one.

Systematic Identification of Culture Conditions for Induction and Maintenance of Naive Human Pluripotency

R. Young, R. Jaenisch, N. Gray, 2014, Cell stem cell.

Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor.

Yan Liu, Fatima Al-Shahrour, Richard A Young, 2014, Cancer cell.

MEK1 mutations confer resistance to MEK and B-RAF inhibition

W. Sellers, L. Garraway, L. Macconaill, 2009, Proceedings of the National Academy of Sciences.

Systematic Identification of Culture Conditions for Induction and Maintenance of Naive Human Pluripotency

R. Young, R. Jaenisch, N. Gray, 2014, Cell stem cell.

Discovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors

P. Jänne, N. Gray, Xianming Deng, 2011, ACS medicinal chemistry letters.

Conformational disturbance in Abl kinase upon mutation and deregulation

John R. Engen, Nathanael S. Gray, N. Gray, 2009, Proceedings of the National Academy of Sciences.

N-Arachidonoyl Dopamine Inhibits NRAS Neoplastic Transformation by Suppressing Its Plasma Membrane Translocation

C. Benes, Jinyan Huang, R. Ren, 2016, Molecular Cancer Therapeutics.

Discovery of potent and selective covalent inhibitors of JNK.

Taebo Sim, Mario Niepel, Scott B Ficarro, 2012, Chemistry & biology.

Identification of Hsp90 inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer

D. Kwiatkowski, Jianming Zhang, I. Malinowska, 2021, bioRxiv.

Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells

N. Gray, Qingsong Liu, C. Mitsiades, 2013, PloS one.

Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer.

Travis J Cohoon, D. Hayes, D. Root, 2013, Cancer discovery.

Chaperones as thermodynamic sensors of drug–target interactions reveal kinase inhibitor specificities in living cells

Sandro Santagata, Susan Lindquist, Luke Whitesell, 2013, Nature Biotechnology.

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.

M. Meyerson, I. Petersen, R. Onofrio, 2011, Cancer discovery.

in squamous cell lung cancer

M. Meyerson, I. Petersen, R. Onofrio, 2011 .

Mutations in the DDR 2 Kinase Gene identify a Novel therapeutic target in squamous cell lung cancer

M. Meyerson, I. Petersen, R. Onofrio, 2011 .

EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.

K. Flaherty, Dennie T. Frederick, N. Gray, 2015, Cancer discovery.

Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors.

Xianming Deng, Ting Zhang, Si-Yang Song, 2017, Cancer research.

A Novel Microtubule Inhibitor Overcomes Multidrug Resistance in Tumors.

Xianming Deng, C. Benes, Ting Zhang, 2018, Cancer research.

In situ kinase profiling reveals functionally relevant properties of native kinases.

N. Gray, H. Weissig, Jiing-Dwan Lee, 2011, Chemistry & biology.

Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site.

Wolfgang Jahnke, Doriano Fabbro, Pascal Furet, 2010, Biochimica et biophysica acta.

GNF-2 Inhibits Dengue Virus by Targeting Abl Kinases and the Viral E Protein.

N. Gray, Jinhua Wang, Jianming Zhang, 2016, Cell chemical biology.

Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis.

Sam W. Lee, J. Clardy, Kiki Chu, 2015, Chemistry & biology.

Small-Molecule Reactivation of Mutant p 53 to Wild-Type-like p 53 through the p 53-Hsp 40 Regulatory Axis Graphical

Sam W. Lee, J. Clardy, Kiki Chu, 2015 .

Small-molecule inhibitors of the c-Fes protein-tyrosine kinase.

S. Knapp, N. Gray, Wenjun Zhou, 2012, Chemistry & biology.

Allosteric Interactions between the Myristate- and ATP-Site of the Abl Kinase

John R. Engen, Nathanael S. Gray, N. Gray, 2011, PloS one.

Expanding the Diversity of Allosteric Bcr-Abl Inhibitors†

G. Rummel, N. Gray, Xianming Deng, 2010, Journal of medicinal chemistry.

Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors

N. Gray, Wenjun Zhou, H. Choi, 2010, Molecular Cancer Therapeutics.

Molecular Cancer apeutics apeutic Discovery overy and Characterization of Novel Mutant Ther 3 Kinase Inhibitors

Ellen, N. Gray, Wenjun Zhou, 2010 .

Discovery of Type II Inhibitors of TGFβ-Activated Kinase 1 (TAK1) and Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2 (MAP4K2)

P. Cohen, N. Gray, K. Westover, 2014, Journal of medicinal chemistry.

Development of 'DFG-out' inhibitors of gatekeeper mutant kinases.

N. Gray, H. Choi, J. Griffin, 2012, Bioorganic & medicinal chemistry letters.

A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl.

Taebo Sim, Yongping Xie, Nathanael S Gray, 2010, Journal of medicinal chemistry.

Broad spectrum alkynyl inhibitors of T315I Bcr-Abl.

N. Gray, Xianming Deng, Jianming Zhang, 2010, Bioorganic & medicinal chemistry letters.

Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.

James D. Griffin, Andrew L. Kung, Taebo Sim, 2010, Blood.

TSC1 involvement in bladder cancer: diverse effects and therapeutic implications

N. Gray, D. Kwiatkowski, Chin-Lee Wu, 2013, The Journal of pathology.

A new ALK inhibitor overcomes resistance to first and secondgeneration inhibitors in NSCLC

Zheng Wang, Qiyuan Li, Yan Liu, 2021 .

Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma.

R. Tibshirani, I. Lossos, Y. Natkunam, 2016, Blood.

A non‐covalent inhibitor XMU‐MP‐3 overrides ibrutinib‐resistant BtkC481S mutation in B‐cell malignancies

Xianming Deng, Si-Yang Song, C. Yun, 2019, British journal of pharmacology.

GDC-0879, a BRAFV600E Inhibitor, Protects Kidney Podocytes from Death.

Joshua A. Bittker, S. Carr, A. Mandinova, 2017, Cell chemical biology.

Upregulation of IGF1R by Mutant RAS in Leukemia and Potentiation of RAS Signaling Inhibitors by Small-Molecule Inhibition of IGF1R

Kwok-Kin Wong, N. Gray, Qingsong Liu, 2014, Clinical Cancer Research.

Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and α-Mangostin

Y. Li, K. Westover, D. Fisher, 2016, PloS one.

Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach.

N. Gray, Qingsong Liu, J. Griffin, 2015, Blood.

Pharmacological Targeting of Vacuolar H+-ATPase via Subunit V1G Combats Multidrug-Resistant Cancer.

A. Dastur, Patricia Greninger, Xianming Deng, 2020, Cell chemical biology.

Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK 7 Inhibitor Citation

Jakob, R. Young, J. Bradner, 2014 .

Systematic Identification of Culture Conditions for Induction and Maintenance of Naive Human Pluripotency

R. Young, R. Jaenisch, N. Gray, 2014, Cell stem cell.

Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies

N. Gray, C. Mitsiades, J. Griffin, 2014, Leukemia.

EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.

K. Flaherty, Dennie T. Frederick, N. Gray, 2015, Cancer discovery.

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1*

D. Sabatini, N. Gray, Qingsong Liu, 2009, Journal of Biological Chemistry.

Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site.

J. Mestan, D. Fabbro, W. Jahnke, 2010, Biochimica et biophysica acta.

Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor.

J. Bradner, N. Gray, Tinghu Zhang, 2014, Cancer cell.

Direct Targeting of β-Catenin by a Small Molecule Stimulates Proteasomal Degradation and Suppresses Oncogenic Wnt/β-Catenin Signaling.

Sam W. Lee, K. Westover, Xianming Deng, 2016, Cell reports.